Type of Cancer
Skin and Soft Tissue
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.